Beta-Adrenergic Modulation of Drug Cue Reactivity

Summary

This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.

Conditions

• Tobacco Use Disorder
• Nicotine Dependence
• Cigarette Smoking

Interventions

DRUG

Propranolol

Propranolol Capsule; 40 mg IR

DRUG

Nicotine Patch

Nicotine Patch; 14 mg

DRUG

Placebo Propranolol

Placebo Capsule, no active ingredients

DRUG

Placebo Patch

Placebo Patch, no active ingredients

Sponsors & Collaborators

• Oklahoma State University Center for Health Sciences

  collaborator OTHER

• Duke University

  collaborator OTHER

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• National Institutes of Health (NIH)

  collaborator NIH

• University of Oklahoma

  lead OTHER

Principal Investigators

• Jason A Oliver, PhD · University of Oklahoma

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Model

CROSSOVER

Eligibility

Min Age

21 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2024-11-26

Primary Completion

2027-03-31

Completion

2027-03-31

FDA Drug

Yes

Countries

• United States

Study Locations